Breast Cancer Clinical Trials in New York

Showing 281-300 of 652 trials

Assessing Depression in a Geriatric Cancer Population

NCT00580476

The goal of this study is to learn more about how we measure depression in elderly cancer patients (patients aged 70 and older). Depression is one of the most common causes of emotional distress in the elderly and continues to be under-recognized. This is a problem because depression can have a negative impact on quality of life. The symptoms of depression are linked to poor health outcomes and higher costs of health care. In fact, depression is one of the top five concerns facing the elderly today.

Breast CancerProstate Cancer

Memorial Sloan Kettering Cancer Center201 participantsStarted Sep 2006

New York, New York, United States

COMPLETED< 1 mile

Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy

NCT04176354

A retrospective observational analysis of de-identified Flatiron Health Analytic Database to describe patient characteristics, treatment patterns and effectiveness of Palbociclib + AI as first-line therapy in HR+/HER2- metastatic breast cancer (MBC) in the US clinical practices.

Metastatic Breast Cancer

Pfizer813 participantsStarted Jan 2019

New York, New York, United States

COMPLETEDPhase 1/2< 1 mile

A Study of ZN-c5 in Subjects With Breast Cancer

NCT03560531

This is a Phase 1/2, open-label, multicenter, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZN-c5 administered orally in subjects with advanced estrogen receptor positive, human epidermal growth factor receptor 2 negative (ER+/HER2-) breast cancer. ZN-c5 will be evaluated both as monotherapy and in combination with palbociclib (IBRANCE®).

Breast Cancer

Zeno Alpha Inc.181 participantsStarted Nov 2018

Tucson, Arizona, United States • Los Angeles, California, United States • Bethesda, Maryland, United States +35 more locations

Assessing Depression in a Geriatric Cancer Population

Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy

A Study of ZN-c5 in Subjects With Breast Cancer

Breast Cancer Trials in Other Cities

Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer

Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer

Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor

Microfluidic Device to Diagnose Leptomeningeal Metastasis in Breast Cancer

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Hair Care Product Use Among Women Of Color

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

Real-life Treatment Patterns With Cyclin-dependent Kinase Inhibitors in Advanced Breast Cancer in Portugal - REVEAL Study

Breast Cancer Index (BCI) Registry

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

Optimizing Functional Recovery of Breast Cancer Survivors

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer

Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer

Motiva Flora Tissue Expander PMCF

Other Conditions in New York